COVID-19 Vaccination Updates for Immunocompromised Individuals

The CDC recently released updates to its Intermediate Clinical Considerations for Use of COVID-19 Vaccines, including updates to COVID-19 vaccination guidelines for individuals who are moderately to severely immunocompromised.

CDC considers people to be moderately or severely immunocompromised if they have:
- Been receiving active cancer treatment for tumors or cancers of the blood.
- Received an organ transplant and are taking medicine to suppress the immune system.
- Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system.
- Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome).
- Advanced or untreated HIV infection.
- Active treatment with high-dose corticosteroids or other drugs that may suppress their immune response.

Updated Vaccination Timeline for Immunocompromised Individuals

The chart below shows doses required to be up to date with COVID-19 vaccination:

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>1st dose</th>
<th>2nd dose</th>
<th>3rd dose</th>
<th>Booster dose*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer-BioNTech (ages 5 years and older)</td>
<td>21 days after 1st dose</td>
<td>at least 28 days after 2nd dose</td>
<td>(at least 3 months after 3rd dose)</td>
<td></td>
</tr>
<tr>
<td>Moderna (ages 18 years and older)</td>
<td>28 days after 1st dose</td>
<td>at least 28 days after 2nd dose</td>
<td>(at least 3 months after 3rd dose)</td>
<td></td>
</tr>
<tr>
<td>Janssen (ages 18 years and older)</td>
<td>Additional dose† (at least 28 days after 1st dose)</td>
<td></td>
<td>Booster dose* (at least 2 months after additional dose)</td>
<td></td>
</tr>
</tbody>
</table>
➢ Note: Time between mRNA primary doses and booster doses has been reduced to 3 months for immunocompromised individuals; it remains 5 months for others.

**Considerations for Monoclonal Antibodies and Vaccination**

There is no need to postpone COVID-19 vaccination following monoclonal antibody administration. However, the administration of EVUSHELD (pre-exposure prophylaxis) for eligible groups should be deferred for at least two weeks following vaccination.

For more information on COVID-19 treatments and therapies: SLOPublicHealth.org/treatments

**Revaccination Doses**

Revaccination (repeating vaccine doses) may be considered for primary vaccination series and any additional or booster doses.

Based on clinical judgement, **even individuals who are up to date on vaccination** might be considered for repeat doses—or even full revaccination—if they:

- Received vaccine(s) during chemotherapy or radiation treatment and have regained immune competence.
- Received vaccine(s) before or during HCT or CAR-T-cell therapy* or other B-cell depleting therapies.

* Revaccination is recommended to start at least 3 months after CAR-T-cell therapy.

If the patient's provider is able to administer the revaccination dose(s), the provider may use their clinical judgement to dose the vaccine(s) outside of the FDA and CDC dosing intervals.

If the caring provider or local pharmacy cannot administer the revaccination dose(s), patients may provide patients with a prescription for a revaccination dose, or refer them for a vaccination appointment at a Public Health clinic: 805-781-5500.

**Upcoming CDC Call to Review Recent COVID-19 Vaccination Updates**

CDC Clinician Outreach & Communication Activity Call:

- Thursday, February 24, 2022 at 11AM
- Topic: Updated Guidance for Clinicians on COVID-19 Vaccines
- www.train.org/main/course/1102449/live_event

**Stay Informed**

- For updates on COVID-19 in SLO County, visit slopublichealth.org/covid19.
- For the full Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States, visit www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html